CDSCO panel to review Serum Institute, Bharat Biotech, Pfizer COVID vaccine applications on December 9
The decision was taken late on Monday evening after the Hyderabad based Bharat Biotech became the third pharmaceutical firm to apply to the Drugs Controller General of India (DCGI) for emergency use authorization for its indigenously developed COVID19 vaccine Covaxin.
New Delhi: An expert committee of the Central Drugs Standard Control Organisation (CDSCO) will meet on Wednesday to review applications of Pfizer, Serum Institute of India, and Bharat Biotech seeking emergency use authorization for their COVID-19 vaccine candidates, official sources said on Monday night.
The decision was taken late on Monday evening after the Hyderabad-based Bharat Biotech became the third pharmaceutical firm to apply to the Drugs Controller General of India (DCGI) for emergency use authorization for its indigenously developed COVID-19 vaccine Covaxin.
Also Read: CDSCO grants medical device registration to three GOQii wearables
The Indian arm of US pharmaceutical giant Pfizer had on December 4 sought approval for its vaccine from the central drug regulator, after the firm secured such clearance in the UK and Bahrain.
The Pune-based Serum Institute of India sought such a nod for the Oxford COVID-19 vaccine, Covishield, on December 6.
"DCGI has already started processing the applications. The subject expert committee on COVID-19 at CDSCO will deliberate on the applications by Pfizer, Serum Institute of India and Bharat Biotech seeking emergency use authorization for their COVID-19 vaccines on December 9," a source said.
At an all-party meeting on December 4, Prime Minister Narendra Modi had expressed hope that a COVID-19 vaccine may be ready in a few weeks.
